Litcius/Paper detail

Carrier-free programmed spherical nucleic acid for effective ischemic stroke therapy via self-delivery antisense oligonucleotide

Wenyan Yu, Cuiping Xuan, Bingbing Liu, Lei Zhou, Na Yin, Enpeng Gong, Zhenzhong Zhang, Yinchao Li, Kaixiang Zhang, Jinjin Shi

2022Nano Research19 citationsDOI

Abstract

Antisense oligonucleotide (ASO) for anti-apoptosis is emerging as a highly promising therapeutic agents for ischemic stroke with complex pathological environment. However, its therapeutic efficacy is seriously limited by a number of challenges including inefficient internalization, low blood-brain barrier (BBB) penetration, poor stability, and potential toxicity of the carrier. Herein, a carrier-free programmed spherical nucleic acid nanostructure is developed for effective ischemic stroke therapy via integrating multifunctional modules into one DNA structure. By co-encoding caspase-3-ASO and transferrin receptor (TfR) aptamer into circle template, the spherical nucleic acid nanostructure (TD) was obtained via self-assembly. The experimental results demonstrated that the developed TD displayed efficient BBB penetration capability (6.4 times) and satisfactory caspase-3 silence effect (2.3 times) due to the dense DNA packaging in TD. Taken together, our study demonstrated that the carrier-free programmed spherical nucleic acid nanostructure could significantly improve the therapeutic efficacy of ischemic stroke and was a promising therapeutic tool for various brain damage-related diseases.

Topics & Concepts

Nucleic acidOligonucleotideApoptosisBlood–brain barrierDNAMaterials scienceNanotechnologyCell biologyCancer researchChemistryBiophysicsMedicineBiologyBiochemistryCentral nervous systemInternal medicineAdvanced biosensing and bioanalysis techniquesRNA Interference and Gene DeliveryDendrimers and Hyperbranched Polymers
Carrier-free programmed spherical nucleic acid for effective ischemic stroke therapy via self-delivery antisense oligonucleotide | Litcius